Clinical trials: Post-COVID
SARS-CoV-2 Infection
Clinical Study of the Third Dose Immunization Schedule of COVID-19 Inactivated Vaccine, (Vero Cells) in Adults Aged 18 Years and Above (6 Months After Two Doses)
To evaluate the immunogenicity and safety of the third dose SARS-CoV-2 Vaccine, Inactivated (Vero Cell) in adults aged 18 years and above, who inoculated the third dose after 6 months since finished two doses schedule of…
- Trial name
- NCT05216484
- Testing
- SARS-CoV-2 Vaccine, Inactivated (Vero Cell)
- Where
- China
- Volunteers
- 480 people, healthy volunteers welcome
- Sponsor
- Chinese Academy of Medical Sciences
COVID-19
HEART Rate Variability Biofeedback in LOng COVID-19 (HEARTLOC)
Long COVID is a common but highly debilitating illness which develops after infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2 or COVID-19).
- Trial name
- HEARTLOC (NCT05228665)
- Testing
- Heart Rate Variability Biofeedback (HRV-B)
- Where
- United Kingdom
- Volunteers
- 30 people
- Sponsor
- University of Leeds
PHYSICAL ACTIVITY
Relationship of Physical Condition and Functionality in Post-covid Patients
Cross-sectional, correlational cohort study where the variables Aerobic endurance (6-minute walk test), Muscle endurance (Medical research council MRC), Flexibility (Sit-and-reach test), Functionality (WHODAS 2.0), Number of days…
- Trial name
- NCT05422950
- Testing
- Relationship between physical condition and functionality in post-covid patients
- Where
- Colombia
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- Universidad Nacional de Colombia
Human ARDS, Coronavirus Infection
Post-intensive Care Follow-up of Patients Hospitalized for an Acute Respiratory Distress Syndrome Caused by COVID-19
For the last years, studies have described the " Post-intensive care Syndrome " (PICS), which consists in alteration of quality of life, cognition, autonomy and psychological disorders within the months after intensive-care.
- Trial name
- RE-CoV-ERY (NCT04619368)
- Testing
- Follow up calls
- Where
- France
- Volunteers
- 52 people
- Sponsor
- University Hospital, Toulouse
COVID-19
To Evaluate the Immunogenicity and Safety of Sequential Booster Immunization of Recombinant Novel Coronavirus Vaccine (CHO Cells) for SARS-CoV-2
An open experimental design was used in this study, and 240 subjects were planned to be enrolled. To evaluate the immunogenicity and safety of recombinant Novel Coronavirus vaccine (CHO cells) after sequential intensification in…
- Trial name
- NCT05895110
- Testing
- Recombinant Novel Coronavirus vaccine (CHO Cells)
- Where
- China
- Volunteers
- 240 people, healthy volunteers welcome
- Sponsor
- Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd.
Covid19
Rehabilitation for Patients With Persistent Symptoms Post COVID-19
A large proportion of persons who have had COVID-19 have reported persisted symptoms as fatigue and dyspnea months post infection which affect activities of daily living.
- Trial name
- NCT04836351
- Testing
- Concentrated rehabilitation for patients with persistent symptoms post COVID-19
- Where
- Norway
- Volunteers
- 20 people
- Sponsor
- Western Norway University of Applied Sciences
Long COVID
A Web-based Platform to Improve Physical Function, Nutrition, and Mindfulness in Patients With Long COVID
Patients with COVID-19 may experience prolonged physical and psychological symptoms after weeks or months of the infection. This may be caused by a combination of factors including poor nutrition, low physical activity, and lack…
- Trial name
- BLEND (NCT05422924)
- Testing
- Web-based platform. (My Viva Plan)
- Where
- Canada
- Volunteers
- 45 people
- Sponsor
- University of Alberta
COVID-19 Virus Disease, Cardiac Complication
Multimodal IMAgery Characterization of Cardiac Damage and Severity After COVID-19 Infection
Coronavirus Disease 2019 (COVID-19) is an infection caused by Severe Acute Respiratory Syndrome Coronavirus (SARS-CoV-2), which affects multiple organ system particularly the lung and heart.
- Trial name
- IMACovid (NCT04753762)
- Where
- France
- Volunteers
- 50 people
- Sponsor
- Central Hospital, Nancy, France
Post-acute Sequelae of SARS-CoV-2 Infection
Cognitive-Sensorimotor Function in Long-COVID
Growing evidence indicates that many people who have chronic post-acute sequelae of SARS-CoV-2 infection (PASC) will experience ongoing neurological and musculoskeletal impairment that can affect gait and balance.
- Trial name
- NCT06850350
- Where
- United States
- Volunteers
- 136 people, healthy volunteers welcome
- Sponsor
- VA Office of Research and Development
Covid19
The Effect of Probiotic Supplementation on SARS-CoV-2 Antibody Response After COVID-19
This study will explore how a well-known probiotic strain L. reuteri DSM 17938 impacts SARS-CoV-2 specific antibody response upon and after infection in healthy adults.
- Trial name
- NCT04734886
- Testing
- L. reuteri DSM 17938 + vitamin D
- Where
- Sweden
- Volunteers
- 161 people, healthy volunteers welcome
- Sponsor
- Örebro University, Sweden
Cognitive Decline, Cognitive Dysfunction
Open-label, Post-marketing, Prospective Study to Assess Impact of COVID-19 on Cognitive Function in Patients
The objective of this study is to compare the impact of the coronavirus disease (SARS-CoV-2, or COVID-19) on cognitive function in the population of patients who have been diagnosed, treated and recovered from the COVID-19…
- Conditions
- Cognitive Decline, Cognitive Dysfunction, Brain Health, Post CoV-2 Syndrome
- Trial name
- COVID19 (NCT04950673)
- Testing
- Cognivue
- Where
- 4 sites in United States
- Volunteers
- 1,000 people, healthy volunteers welcome
- Sponsor
- Cognivue, Inc.
COVID-19 Pneumonia
Evaluation of Immunogenicity and Safety of COVID-19 Vaccine (Produced in Beijing) in Patients With Hypertension and/or Diabetes
To evaluate the post-marketing immunogenicity and safety of the inactivated severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccine (Vero cells) in patients aged 60 years or older with hypertension and/or diabetes…
- Trial name
- NCT05065879
- Testing
- COVAX
- Where
- 5 sites in China
- Volunteers
- 1,440 people, healthy volunteers welcome
- Sponsor
- China National Biotec Group Company Limited
SARS-CoV-2
Post-Marketing Safety Study in Japan in Participants With High Risk of Severe Exacerbation of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) mRNA-1273 COVID-19 Vaccine
The goal of this study is to assess the adverse events in the acute phase observed after vaccination with the mRNA-1273 vaccine in persons with underlying diseases who are considered to have a high risk of severe exacerbation…
- Trial name
- NCT05894525
- Where
- Japan
- Volunteers
- 8,844 people
- Sponsor
- ModernaTX, Inc.